Merck completes acquisition of Prometheus Biosciences
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Subscribe To Our Newsletter & Stay Updated